Navigation Links
Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence

Aromatase Inhibitors drug, Femara given after 5 years of Tamoxifen therapy is found to give protection against occurrence of Breast cancer recurrence. Breast cancer is the second leading cause of cancer// in women. Breast cancer mostly occurs in post menopausal women and various risk factors are attributed for the occurrence of breast cancer.

Treatment of breast cancer initially involves removal of the entire breast or part of the breast with the cancer lump followed by Radiation therapy and Chemotherapy. Cytotoxic drugs are given as chemotherapy for patients with breast cancer; usually 6 cycles of chemotherapeutic drugs are given such as Cyclophosphamide, 5 flurouracil, adiramycin. After these procedures 5 years of Tamoxifen therapy is recommended for post menopausal women. Tamoxifen therapy is recommended only for 5 years as studies in which tamoxifen given for more than 5 years shows no difference. Tamoxifen acts as an anti-estrogen by which it competitively inhibits the estrogens produced by the body, as estrogen is used up by the cancer cell for its growth and production. Metastasis and recurrence occurs in some cancer patients, though the chance of metastasis is very less as only 1 in 10000 cells has the capacity to reach the blood stream and cause cancer in a new organ.

Recurrence mostly occurs due to pitfalls or not properly taking therapy or tablets, even tamoxifen resistance developed by the patient may also lead to recurrence. Recurrence may occur at the same initial cancer site called as loco-regional or in a new site.

The new study using Femara Aromatase Inhibitors after 5 years of Tamoxifen therapy as found to give protection against occurrence of recurrence. Aromatase inhibitors lower the levels of estrogen in the body by acting on the Aromatase enzyme involved in making estrogen. The study was conducted in 5000 postmenopausal women who have finished their 5 years tamoxifen therapy and they were given femara for an other 5 years. Though the overall survival rates of both the group were same, the group taking femara had a significant lower risk of breast cancer recurrence. The patients with lymph node positive cancer had a significant better survival rate taking femara. Though femara had some side effects such as osteoporosis in 8.1 %, hot flashes in 58 % and hair loss, and these side effects are very common and less significant compared to its benefits.
'"/>




Related medicine news :

1. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
2. Early Switch to an Aromatase Inhibitor Increases Survival
3. LipB Protein Inhibitors Help To Fight Against TB
4. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
5. ACE Inhibitors For Vascular Disease Patients
6. Green Tea and COX-2 Inhibitors Combine to Slow Growth of Prostate Cancer
7. Femara: The Wonder Drug to Prevent Relapse of Breast Cancer.
8. Thyroid hormone treatment hastens recovery after cardiac surgery
9. Morning after pill effective up to five days after having unprotected sex
10. Liver donors can thrive after transplant
11. Recouping blood flow after a stroke
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
Breaking Medicine Technology: